BioCentury
ARTICLE | Company News

Bio-Path, Thomas Jefferson University deal

July 18, 2016 7:00 AM UTC

Bio-Path and the university partnered to develop Bio-Path’s DNAbilize systemic antisense immunotherapy to treat brain cancer. The DNAbilize liposomal delivery and antisense technology distributes nucl...